Banks registration document schedule

The Parties will cooperate to enhance further implementation of the EU acquis in all transport modes mentioned in relevant annexes of the Association Agreement and to support Georgia in

Asset backed securities registration document schedule

This document is a summary of the European public assessment report (EPAR) for Ablavar.

This document is a summary of the European public assessment report (EPAR) for Aptivus.

This document is a summary of the European Public Assessment Report (EPAR) for Arepanrix.

This document is a summary of the European public assessment report (EPAR) for Arixtra.

This document is a summary of the European Public Assessment Report (EPAR) for ATryn.

This document is a summary of the European Public Assessment Report (EPAR) for Avaglim.

This document is a summary of the European Public Assessment Report (EPAR) for Avandamet.

This document is a summary of the European Public Assessment Report (EPAR) for Avandia.

This document is a summary of the European public assessment report (EPAR) for Avonex.

This document is a summary of the European Public Assessment Report (EPAR) for BeneFIX.

This document is a summary of the European public assessment report (EPAR) for Brinavess.

This document is a summary of the European public assessment report (EPAR) for Cerezyme.

This document is a summary of the European Public Assessment Report (EPAR) for Cholestagel.

This document is a summary of the European Public Assessment Report (EPAR) for Circadin.

This document is a summary of the European Public Assessment Report (EPAR) for Combivir.

This document is a summary of the European public assessment report (EPAR) for Cubicin.

This document is a summary of the European public assessment report (EPAR) for DaTSCAN.

This document is a summary of the European Public Assessment Report (EPAR) for DepoCyte.

This document is a summary of the European Public Assessment Report (EPAR) for Docefrez.

This document is a summary of the European Public Assessment Report (EPAR) for DuoPlavin.

This document is a summary of the European public assessment report (EPAR) for DuoTrav.

This document is a summary of the European public assessment report (EPAR) for Dynastat.

This document is a summary of the European Public Assessment Report (EPAR) for Epivir.

This document is a summary of the European public assessment report (EPAR) for Ferriprox.

This document is a summary of the European public assessment report (EPAR) for Firdapse.

This document is a summary of the European Public Assessment Report (EPAR) for Focetria.

This document is a summary of the European Public Assessment Report (EPAR) for Humenza.

This document is a summary of the European public assessment report (EPAR) for Ifirmasta.

This document is a summary of the European Public Assessment Report (EPAR) for ImmunoGam.

This document is a summary of the European public assessment report (EPAR) for Intrinsa.

This document is a summary of the European public assessment report (EPAR) for Invirase.

This document is a summary of the European Public Assessment Report (EPAR) for Ixiaro.

This document is a summary of the European public assessment report (EPAR) for Kivexa.

This document is a summary of the European Public Assessment Report (EPAR) for Lantus.

This document is a summary of the European public assessment report (EPAR) for Livensa.

This document is a summary of the European Public Assessment Report (EPAR) for Lyrica.

This document is a summary of the European public assessment report (EPAR) for Mepact.

This document is a summary of the European Public Assessment Report (EPAR) for Mirapexin.

This document is a summary of the European public assessment report (EPAR) for Mircera.

This document is a summary of the European public assessment report (EPAR) for Myclausen.

This document is a summary of the European Public Assessment Report (EPAR) for NovoMix.

This document is a summary of the European Public Assessment Report (EPAR) for Onsenal.